April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Molecular Imaging of Ocular Distribution of Bevacizumab in Rabbit Eye Following an Intravitreal Injection of 64Cu-DOTA-Bevacizumab
Author Affiliations & Notes
  • Wu Yang
    PPDM, Allergan, Irvine, California
  • Zheng Wang
    Discovery Center, MPI Research, Inc., Mattawan, Michigan
  • Renee Paau
    PPDM, Allergan, Irvine, California
  • Mohammed Farhoud
    Discovery Center, MPI Research, Inc., Mattawan, Michigan
  • Brian Knapp
    Discovery Center, MPI Research, Inc., Mattawan, Michigan
  • Glenn Smits
    Discovery Center, MPI Research, Inc., Mattawan, Michigan
  • Devin Welty
    PPDM, Allergan, Irvine, California
  • Footnotes
    Commercial Relationships  Wu Yang, None; Zheng Wang, None; Renee Paau, None; Mohammed Farhoud, None; Brian Knapp, None; Glenn Smits, None; Devin Welty, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1702. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wu Yang, Zheng Wang, Renee Paau, Mohammed Farhoud, Brian Knapp, Glenn Smits, Devin Welty; Molecular Imaging of Ocular Distribution of Bevacizumab in Rabbit Eye Following an Intravitreal Injection of 64Cu-DOTA-Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1702.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To determine the ocular distribution of Bevacizumab following intravitreal administration in rabbit eye using positron emission tomography (microPET).

 
Methods:
 

Bevacizumab was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and tagged with 64Cu for PET imaging. 64Cu-DOTA-Bevacizumab at doses of 14.5µCi/14µg/12.5µl and 101 µCi/97µg/12.5µl were injected into the mid-vitreous of female New Zealand White rabbits. Under anesthesia the head was imaged with a microPET scanner from 5-120 minutes (dynamic imaging), and at 5, 20, 28, and 44 hour post-injection with computed tomography (microCT) for co-registration of PET and CT images. Radioactivity was quantitated to determine the in vivo biodistribution of 64Cu-DOTA- Bevacizumab.

 
Results:
 

From 5-120 minutes after injection, 64Cu-DOTA-Bevacizumab migrated from the mid-vitreous posteriorly to form an elliptical shape corresponding to the vitreous-retina interface (Figure 1). Peak accumulation on the retina surface was reached at 2 hr. Between 5 and 44 hour post-injection, 64Cu-DOTA-Bevacizumab spread to form a ball-shaped pattern around the outer surface of the eye. In contrast, 64Cu-DOTA unconjugated to Bevacizumab was rapidly eliminated from the vitreous humor within 2 hrs.

 
Conclusions:
 

The biodistribution of 64Cu-DOTA-Bevacizumab was successfully described in the rabbit eye by non-invasive PET/CT imaging technology. Dynamic imaging revealed a distinct pattern of movement and distribution of 64Cu-DOTA-Bevacizumab towards posterior retina.Figure 1. A microPET/CT image of 64Cu-DOTA-Bevacizumab (OS) or 64Cu-DOTA (OD) distribution in NZW rabbit eye 5 hr after intravitreal injection  

 
Keywords: imaging/image analysis: non-clinical • vitreous • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×